HomeAI · summaries
Storia in 2 fonti
Milvexian did not reduce ischemic risk in trial of patients with recent ACS
MUNICH — Milvexian did not lower risk for ischemic events compared with placebo in patients who experienced a recent ACS, but also did not increase bleeding risk, a speaker reported.The LIBREXIA trial evaluating the small-molecule factor XIa inhibitor milvexian (Bristol Myers Squibb/Johnson & Johnson) in patients at risk for recurrent ischemic events after an ACS event was halted early
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Milvexian did not reduce ischemic risk in trial of patients with recent ACS
MUNICH — Milvexian did not lower risk for ischemic events compared with placebo in patients who experienced a recent ACS, but also did not increase bleeding risk, a speaker…
- ·
medpagetoday.com
Factor XIa Inhibitor Shows No Benefit After Acute Coronary Syndrome
Milvexian was safe, but not effective in preventing events in high-risk patients